WO2000021486A2 - Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid - Google Patents
Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid Download PDFInfo
- Publication number
- WO2000021486A2 WO2000021486A2 PCT/US1999/023591 US9923591W WO0021486A2 WO 2000021486 A2 WO2000021486 A2 WO 2000021486A2 US 9923591 W US9923591 W US 9923591W WO 0021486 A2 WO0021486 A2 WO 0021486A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rxr
- retinoid
- skin
- rar
- irradiation
- Prior art date
Links
- 150000004492 retinoid derivatives Chemical class 0.000 title claims abstract description 27
- 208000010011 Vitamin A Deficiency Diseases 0.000 title abstract description 11
- 230000002265 prevention Effects 0.000 title description 2
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 claims abstract description 84
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 claims abstract description 84
- 241000282414 Homo sapiens Species 0.000 claims abstract description 80
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract description 69
- 229930002330 retinoic acid Natural products 0.000 claims abstract description 69
- 229960001727 tretinoin Drugs 0.000 claims abstract description 64
- 108091008679 retinoid hormone receptors Proteins 0.000 claims abstract description 48
- 102000027483 retinoid hormone receptors Human genes 0.000 claims abstract description 47
- 230000009467 reduction Effects 0.000 claims abstract description 36
- 230000002829 reductive effect Effects 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 18
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 16
- 102000003702 retinoic acid receptors Human genes 0.000 claims description 11
- 108090000064 retinoic acid receptors Proteins 0.000 claims description 11
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 9
- 230000005855 radiation Effects 0.000 claims description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 229960003471 retinol Drugs 0.000 claims description 3
- 235000020944 retinol Nutrition 0.000 claims description 3
- 239000011607 retinol Substances 0.000 claims description 3
- 206010047626 Vitamin D Deficiency Diseases 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 abstract description 56
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 abstract description 38
- 108090000623 proteins and genes Proteins 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 25
- 238000001727 in vivo Methods 0.000 abstract description 23
- 102000004169 proteins and genes Human genes 0.000 abstract description 17
- 102100038504 Cellular retinoic acid-binding protein 2 Human genes 0.000 abstract description 14
- 108010011716 cellular retinoic acid binding protein II Proteins 0.000 abstract description 14
- 230000006698 induction Effects 0.000 abstract description 14
- 230000014509 gene expression Effects 0.000 abstract description 12
- 102000009310 vitamin D receptors Human genes 0.000 abstract description 12
- 108050000156 vitamin D receptors Proteins 0.000 abstract description 12
- 108010022037 Retinoic Acid 4-Hydroxylase Proteins 0.000 abstract description 10
- 102000012211 Retinoic Acid 4-Hydroxylase Human genes 0.000 abstract description 10
- 206010051246 Photodermatosis Diseases 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 6
- 230000008845 photoaging Effects 0.000 abstract description 6
- 230000003247 decreasing effect Effects 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 230000037311 normal skin Effects 0.000 abstract description 3
- 230000004215 skin function Effects 0.000 abstract description 3
- 230000002939 deleterious effect Effects 0.000 abstract description 2
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 abstract 1
- 208000005623 Carcinogenesis Diseases 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 229960005084 calcitriol Drugs 0.000 abstract 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 abstract 1
- 230000036952 cancer formation Effects 0.000 abstract 1
- 231100000504 carcinogenesis Toxicity 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 150000002266 vitamin A derivatives Chemical class 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 121
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 description 75
- 108091008760 retinoic acid receptors γ Proteins 0.000 description 75
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 18
- 102100023132 Transcription factor Jun Human genes 0.000 description 15
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 102000034527 Retinoid X Receptors Human genes 0.000 description 11
- 108010026102 Vitamin D3 24-Hydroxylase Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 102000013387 Vitamin D3 24-Hydroxylase Human genes 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000004043 responsiveness Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 238000000636 Northern blotting Methods 0.000 description 7
- 238000007390 skin biopsy Methods 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000000453 Skin Neoplasms Diseases 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091027981 Response element Proteins 0.000 description 4
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 4
- 229930003316 Vitamin D Natural products 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 108091008726 retinoic acid receptors α Proteins 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001378 electrochemiluminescence detection Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108091008761 retinoic acid receptors β Proteins 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000640876 Homo sapiens Retinoic acid receptor RXR-beta Proteins 0.000 description 2
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 102100034253 Retinoic acid receptor RXR-beta Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000004734 cutaneous carcinogenesis Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001403 relative X-ray reflectometry Methods 0.000 description 2
- 235000020945 retinal Nutrition 0.000 description 2
- 239000011604 retinal Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 102000004217 thyroid hormone receptors Human genes 0.000 description 2
- 108090000721 thyroid hormone receptors Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 102100027518 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Human genes 0.000 description 1
- 101710191280 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 101000640882 Homo sapiens Retinoic acid receptor RXR-gamma Proteins 0.000 description 1
- 101001112293 Homo sapiens Retinoic acid receptor alpha Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 102100034262 Retinoic acid receptor RXR-gamma Human genes 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108700042354 Vitamin D Response Element Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- -1 all-trows Chemical compound 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 206010004398 benign neoplasm of skin Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 102000027507 nuclear receptors type II Human genes 0.000 description 1
- 108091008686 nuclear receptors type II Proteins 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000026938 proteasomal ubiquitin-dependent protein catabolic process Effects 0.000 description 1
- 239000011546 protein dye Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- All-trans retinoic acid is a critical regulator of cell growth and differentiation 5 in developing and adult mammalian skin.
- Two families of nuclear retinoid receptors, retinoic acid receptors (denoted RARs) and retinoid X receptors (denoted RXRs) mediate the biological effects of RA.
- Each family of nuclear retinoid receptors is comprised of three subtypes, ⁇ , ⁇ , and ⁇ , which are ligand-activated transcription factors.
- RAR- ⁇ and RXR- ⁇ function as heterodimers to mediate the pleiotropic biological activities of
- RAR transcripts RAR- ⁇ and RAR- ⁇ are decreased in benign skin tumors in mice and are essentially absent in undifferentiated squamous cell carcinomas in man.
- retinoids are effective for treating or preventing certain kinds of cancers, in both animal and human models.
- retinoid inhibition of cell growth correlates with RAR- ⁇ expression.
- RA has proven to be effective in inhibiting tumor promoter- induced transformation in cultured cells.
- RAR- ⁇ mRNA selectively lost in premalignant oral lesions was restored by treatment with 13 -cis retinoic acid.
- UN irradiation is a complete carcinogen, capable of causing cell transformation and promoting tumor formation.
- UN irradiation causes D ⁇ A damage that can result in mutations as a consequence of imperfect D ⁇ A repair. Such mutations can ultimately lead to cell transformation.
- UN irradiation is a complete carcinogen, capable of causing cell transformation and promoting tumor formation.
- UN irradiation causes D ⁇ A damage that can result in mutations as a consequence of imperfect D ⁇ A repair. Such mutations can ultimately lead to cell transformation.
- KB the activation of which lead(s) to complex secondary changes in expression of multiple target genes.
- These genes are involved in arrest of the Gl phase of the cell cycle, D ⁇ A repair mechanisms, and p53-dependent programmed cell death, among other functions.
- Many UN-inducible genes such as c-jun, c-fos, c-myc, plasminogen activator, coUagenases,
- 35 and ornithine decarboxylase are involved in tumor progression in a variety of cancers.
- UV irradiation of human skin causes reductions in RAR- ⁇ protein and mRNA and RXR- ⁇ protein and mRNA, and so it would also be useful to inhibit the loss/reduction in these proteins and the mRNA coding therefor.
- topical pretreatment with a retinoid prior to UV exposure inhibits the reductions in RAR- ⁇ and RXR- ⁇ proteins caused by UV radiation.
- Retinoid receptors are necessary for human skin to respond to vitamin D (e.g., 1,25-dihydroxyvitamin D 3 ). Accordingly, the present method includes inhibiting the loss of at least one type of retinoid receptor after exposure of human skin to UV radiation by topically pretreating the skin later to be exposed to the UV radiation with a retinoid, preferably in amounts of 0.01% to 5%, more preferably 0.05% to 1%.
- this invention also includes preventing functional vitamin A deficiency in human skin because of UV exposure, which method comprises pretreating the skin to be exposed to UV radiation with a retinoid, preferably in amounts of 0.01% to 5%, more preferably 0.05% to 1%. Pretreatment with the retinoid (or a compatible mixture of retinoids) preferably occurs at least 8, more preferably 12, and most preferably about 24 hours prior to exposure to UV radiation.
- Fig. 1 Ultraviolet irradiation reduces nuclear retinoid receptor proteins and mRNAs in adult human skin in vivo.
- A Time course of reductions of RAR- ⁇ protein
- FIG. 2 Repeated exposure to UV irradiation causes sustained reduction of RXR- ⁇ but not RAR- ⁇ in human skin in vivo.
- A Northern analyses of RAR- ⁇ mRNA (open bars) and RXR- ⁇ mRNA (hatched bars) were performed on total RNA extracted from UV-irradiated and non-irradiated human skin. Separate skin sites received one, two, or three exposures to IMED UV at 24-hour intervals. Skin was obtained for analyses eight hours following the last UV exposure. Inset shows representative Northern blots for RAR- ⁇ RXR- ⁇ and 36B4 (internal control). Retinoid receptor hybridization signals were normalized to those of 36B4.
- Fig. 3 Pretreatment with topical RA reduces loss of RAR- ⁇ and RXR- ⁇ in UV- irradiated human skin in vivo.
- Adult human skin was treated on two sites with vehicle (VEH) and on two sites with 0.1% all-trans retinoic acid (RA).
- UV (2MED) was administered to skin 24 hours after application of vehicle or RA.
- Skin biopsies were obtained eight or sixteen hours following exposure to UV.
- RAR- ⁇ (open bars) and RXR- ⁇ (hatched bars) protein levels were determined by Western blot analyses. Insets show representative Western blots of RAR- ⁇ and RXR- ⁇ proteins.
- UV irradiation abolishes responsiveness to all-trans retinoic acid (RA), but not 1 ,25-dihydroxyvitamin D 3 in human skin in vivo.
- RA all-trans retinoic acid
- A UV irradiation blocks RA induction of CRABP-II mRNA in human skin in vivo. UV (2MED) was administered to adult human skin two hours before application of RA or vehicle (VEH). Skin was obtained for Northern analyses eight hours following application of RA or vehicle. Inset shows representative Northern blots for CRABP-II mRNA and 36B4 (internal control). CRABP-II hybridization signals were normalized to those of 36B4.
- UV irradiation blocks induction of RA 4-hydroxylase (RA 4-OHase) mRNA by RA in human skin in vivo. UV (2MED) was administered to adult human skin six hours before application of RA or vehicle. Skin was obtained for Northern analyses 24 hours following application of RA or vehicle. Inset shows representative Northern blots for RA 4-OHase mRNA and 36B4 (internal control). RA 4-hydroxylase hybridization signals were normalized to those of 36B4.
- Ultraviolet irradiation reduces retinoid receptor mRNA and protein levels in human skin in vivo.
- RAR- ⁇ and RXR- ⁇ proteins the major nuclear retinoid receptors in human skin.
- Nuclear extracts from UV-irradiated and non-irradiated human skin biopsies were analyzed for nuclear retinoid receptor protein levels by Western blot.
- Significant reductions in RAR- ⁇ and RXR- ⁇ proteins were observed following UV irradiation (Fig. 1 A).
- Reductions in both RAR- ⁇ and RXR- ⁇ proteins were detected as early as one and two hours post UV exposure, respectively, and remained reduced for at least 24 hours (Fig. 1 A).
- RXR- ⁇ protein Eight hours after UV exposure, RXR- ⁇ protein was reduced over 70%, and RAR- ⁇ protein was reduced over 80% in UV-irradiated skin, compared to non-irradiated skin (Fig. 1 A). At 16 hours post UV, RXR- ⁇ protein was further reduced (85%), while RAR- ⁇ protein recovered 20%, to one-half of its original level. By 48 hours after UV irradiation, RXR- ⁇ and RAR- ⁇ protein levels returned to values found in non-irradiated skin (Fig. 1 A).
- RAR- ⁇ mRNA were decreased approximately 85% and 75%, respectively, relative to non- irradiated skin at eight hours post UV (Fig. IB).
- RAR- ⁇ mRNA returned to the non- irradiated control level by 16 hours post UV, whereas RXR- ⁇ mRNA remained 60% reduced for at least 24 hours following exposure to UV (Fig. IB).
- UV irradiation reduced both RAR- ⁇ and RXR- ⁇ mRNA levels in a dosedependent manner (Fig. 1C).
- Significant reductions in mRNA for both retinoid receptors were evident in human skin exposed to one-half the amount of UV that causes skin reddening (t ' .e., 0.5 MED).
- retinoid receptor mRNA can be reduced by doses of UV that do not cause any noticeable skin reddening.
- RAR- ⁇ and RXR- ⁇ human skin also expresses detectable RAR- ⁇ protein. UV irradiation reduced RAR- ⁇ protein in a manner similar to that described above for RAR- ⁇ and RXR- ⁇ (data not shown). We could not reliably detect RAR- ⁇ , RXR- ⁇ , or RXR- ⁇ proteins in either untreated or UV-irradiated human skin.
- RAR- ⁇ (Fig. 2A). As expected, both RAR- ⁇ and RXR- ⁇ mRNA were decreased eight hours after the first exposure to UV. Eight hours after the second exposure, RAR- ⁇ mRNA exhibited a slight recovery relative to the level observed after the first UV exposure, while RXR- ⁇ mRNA was further decreased, to about 25% of its level in non- irradiated skin. Eight hours following the third UV exposure, RAR- ⁇ mRNA had recovered to approximately 85% of the level in non-irradiated skin, while RXR- ⁇ mRNA remained reduced at 35% of control levels (Fig. 2A). We next examined the effect of multiple UV exposures on RAR- ⁇ and RXR- ⁇ protein levels (Fig. 2B).
- Skin was exposed three times to 1 MED UV at 24-hour intervals and analyzed eight hours after the last exposure (a total of 56 hours after the first exposure). For comparison, separate sites on each subject were also irradiated once with 1 MED UV, and skin was analyzed eight hours and 56 hours after irradiation. As expected,
- RAR- ⁇ and RXR- ⁇ protein levels were reduced eight hours following a single UV exposure (Fig. 2B).
- both RAR- ⁇ and RXR- ⁇ proteins had returned to levels comparable to those in non-irradiated skin (Fig. 2B).
- RXR- ⁇ protein remained significantly reduced, compared to its level in non-irradiated skin.
- RAR- ⁇ protein returned to the original level seen in non-irradiated skin, following three UV exposures.
- Pretreatment with topical RA partially blocks UV-induced loss of RAR- ⁇ and RXR- ⁇ proteins in human skin.
- RXRs heterodimerize with other nuclear receptors, including thyroid hormone receptors, peroxisome proliferator-activated receptor, and vitamin D 3 receptor (VDR).
- the promoter of the vitamin D 24-hydroxylase gene contains a vitamin D response element that is activated by 1,25-dihydroxyvitamin D 3 in human skin. This induction involves transcriptional activation by VDR/RXR heterodimers. We therefore examined whether UV alters 1,25-dihydroxyvitamin D 3 induction of vitamin D 24-hydroxylase in human skin.
- UV-induced loss of nuclear retinoid receptor proteins was rapid, occurring within one to two hours after a single exposure to UV.
- UV-induced loss of RAR- ⁇ mRNA lagged behind loss of RAR- ⁇ protein, suggesting that the initial reduction of RAR- ⁇ protein may have resulted from accelerated breakdown, rather than reduced synthesis.
- UV-induced loss of RXR- ⁇ mRNA and protein were coincident, making it difficult to assess the relative contribution of reduced mRNA and accelerated breakdown to the initial reduction of RXR- ⁇ protein.
- UV generates reactive oxygen species that damage proteins through chemical oxidation. Oxidized proteins are recognized and degraded by proteasome and other disposal pathways.
- RXR- ⁇ This mechanism is analogous to that reported for stabilization of the vitamin D receptor by its ligand, 1,25-dihydroxyvitamin D 3 .
- RAR- ⁇ and RXR- ⁇ mRNA began to recover between 8 and 16 hours following a single UV exposure. By 16 hours after UV irradiation, RAR- ⁇ mRNA was fully recovered, while RXR- ⁇ mRNA remained 50% reduced.
- RAR- ⁇ mRNA and protein had recovered to their normal levels, whereas RXR- ⁇ mRNA and protein remained significantly reduced.
- RAR- ⁇ appears to become refractory to the effects of UV irradiation, whereas RXR- ⁇ does not.
- the reason for this difference is not known.
- the ratio of RXR- ⁇ to RAR- ⁇ is approximately five to one in normal human skin (Fisher, G.J. et al., "Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin," J Biol Chem 269, 20629-20635 (1994)). Following multiple UV exposures, this ratio becomes approximately one to one due to reduced RXR- ⁇ levels.
- RAR- ⁇ must heterodimerize with RXR- ⁇ to function in skin.
- RXR- ⁇ is a shared partner with several other nuclear receptors in skin, including vitamin D receptors, thyroid hormone receptors, and peroxisome proliferator-activated receptors. It is likely, therefore, that retinoid responsiveness will be limited in skin chronically exposed to UV irradiation by reduced levels of RXR- ⁇ , even though RAR- ⁇ levels may not be significantly reduced. In contrast to the observed loss of retinoid responsiveness in UV-irradiated human skin, UV irradiation did not alter the ability of human skin to respond to 1,25-dihydroxyvitamin D 3 . This finding indicates that UV selectively interferes with retinoid signaling.
- the vitamin D receptor in human skin binds to DR3 response elements exclusively as a heterodimer with RXR.
- the vitamin D 24-hydroxylase gene contains DR3 response elements in its promoter, which confer VDR/RXR-mediated induction by 1,25- dihydroxyvitamin D 3 .
- the RXR ligand 9-cis RA synergistically augments 1,25-dihydroxyvitamin D 3 induction of vitamin D 24-hydroxylase, indicating that, in human skin, RXR functions in the vitamin D response.
- Human skin contains approximately twenty times more RXR- ⁇ than vitamin D receptors (Li et al. , submitted manuscript).
- retinoid receptors alter the activity of other families of transcription factors. Most notably, retinoid receptors can interfere with the activity of transcription factor AP-1. UV irradiation activates AP-1 in human skin in vivo, and this activity follows a time course similar to that described above for UV-induced loss of retinoid receptors.
- UV simultaneously reduces retinoid receptors and induces AP-1.
- AP-1 induction in human skin occurs through increased expression of c-Jun and activation of c-Jun N-terminal kinase (JNK) activity.
- JNK c-Jun N-terminal kinase
- retinoid receptors can negatively regulate AP-1, retinoid receptor loss following UV irradiation could further enhance AP-1 activation in UV-irradiated human skin.
- UV irradiation from the sun is the primary causative agent for premature skin aging (photoaging) and skin cancer, which is the most prevalent form of human malignancy.
- AP- 1 activity is a critical mediator of photoaging in humans, and is required for tumor progression in the mouse model of skin carcinogenesis.
- Retinoic acid antagonizes AP-1 action in a human photoaging model, and retinoid receptors are reduced during skin tumor progression, and in approximately 90% of skin tumors in humans.
- a single UV exposure caused reversible reductions in RAR- ⁇ and RXR- ⁇ while daily UV exposures resulted in a sustained reduction of RXR- ⁇ but not RAR- ⁇ .
- UV exposures that were too little to cause any skin reddening resulted, nevertheless, in statistically significant reductions of RAR- ⁇ and RXR- ⁇ .
- Reduced retinoid receptors result in a state of functional vitamin A deficiency that, in conjunction with activated AP-1, could promote photoaging and tumor development in skin.
- Use of RA may prevent, at least in part, loss of retinoid receptors and thereby act to mitigate the participation of AP-1 in photoaging and skin carcinogenesis.
- Retinoids in general are useful for preventing the functional vitamin D deficiency in human skin caused by exposure to UV radiation.
- Retinoids besides vitamin A acid (retinoic acid (RA)), include retinol (vitamin A) and natural and synthetic analogs of vitamin A, vitamin A aldehyde (retinal), including all-trows, 9-cis, and 13-cts retinoic acid), etretinate, and others as described in EP-A2-0379367, US 4,887,805, and US 4,888,342
- Patents numbered: 5,514,825; 5,698,700; 5,696,162; 5,688,957; 5,677,451; 5,677,323;
- Keratome biopsies were obtained from healthy adult human volunteers as previously described. (See Fisher, G. J. et al, "Cellular, immunologic and biochemical characterization of topical retinoic acid-treated human skin," J Invest Dermatol 96, 699-707 (1991).) All procedures involving human subjects were approved by the University of Michigan Institutional Review Board prior to initiation of the study, and all subjects provided written informed consent.
- F36T12 ERE-VHO UVB tubes F36T12 ERE-VHO UVB tubes.
- a Kodacel TA4011/407 filter was mounted 4 cm in front of the tubes to remove wavelengths below 290 nm (UVC).
- Irradiation intensity was monitored using an IL443 phototherapy radiometer and a SED240/UVB/W photodetector (International Light, Newbury, MA).
- Spectralradiometry was performed using an Optronic Laboratories OL 754 system. Total irradiance (290-800 nm) was 1.49 x 10 '3 w/cm 2 at a distance 17 inches from the source.
- UVB UVB
- UVA2 320-340 nm
- UVA1 UVA1
- UVA1 UVA1
- 26% visible and near infrared 400-800 nm
- the minimal erythema dose (MED) for each subject was determined 24 hours after irradiation.
- One MED for all subjects ranged from 30-50 mJ/cm 2 .
- RA and its vehicle (70% ethanol, 30% polyethyleneglycol, 0.05% BHT) were applied to skin under occlusion,
- RA 24 hours prior to UV treatment.
- RA was applied to skin two hours after exposure to UV, and skin was obtained eight hours after treatment with RA.
- RA 4-hydroxylase mRNA RA was applied six hours after UV irradiation, and skin was obtained 24 hours after treatment with RA.
- 1,25- dihydroxyvitamin D 3 was applied to skin six hours after UV irradiation, and skin was obtained 24 hours later for measurement of vitamin D 24-hydroxylase mRNA.
- RNA isolation and Northern blot analysis For isolation of total RNA, skin biopsies were immediately frozen in liquid nitrogen and stored at -80 ° C until subsequent isolation of RNA. Frozen skin was ground into a fine powder in liquid nitrogen, and total RNA was isolated as previously described. RNA samples (40 ⁇ g total RNN determined by OD 260nm absorption spectrophotometry) were electrophoretically size-fractionated on 1.2% formaldehyde-agarose gels, transferred to nylon membranes (Schleicher & Schuell, Keene, NH) and UV cross-linked.
- DMEM Dulbecco's modified Eagle's medium
- DMEM Dulbecco's modified Eagle's medium
- fetal calf serum 10% fetal calf serum
- Extracts were aliquoted and stored at -80°C for future use. Protein determinations were carried out according to the method of Bradford, with BSA as standard (see Bradford, M., "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding," AnalBiochem 72, 248-251(1976)).
- RAR- ⁇ , RAR- ⁇ , RAR- ⁇ , RXR- ⁇ , and RXR- ⁇ were transiently over-expressed in Hela cells using Superfect transfection reagent (Qiagen, Chatsworth, CA) according to the manufacturer's instructions. Twenty-four hours after transfection, culture media were removed, cells were scraped into Eppendorf tubes, and lysed in buffer containing 50 mM Tris-HCl (pH 8.0), 5 mM EDTA, 150 mM NaCl, 0.5% NP-40, and 1 mM DTT. Cells were sonicated for 30 sec. on ice, using a probe sonicator.
- the homogenate was centrifuged at 15,000 x g for 20 min. to remove particulate material. The supernatant was collected as the source of recombinant retinoid receptors, which were used as standard for Western analyses, as described in the text.
- the receptor-antibody complexes were detected by enhanced chemiluminescence (ECL) or by enhanced chemifluorescence (ECF) (ECL and ECF Western blotting systems available from Amersham Corp., Arlington Heights, IL). Bands were quantified by laser densitometry or by STORM Phosphorlmager. Statistics. Comparisons among treatment groups were made with the paired t test. Multiple pairwise comparisons were made with the Tukey Studentized Range test. All/? values are two-tailed, and significant when ⁇ 0.05.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14234999A IL142349A0 (en) | 1998-10-14 | 1999-10-12 | A topical composition containing a retinoid |
JP2000575462A JP2003524604A (en) | 1998-10-14 | 1999-10-12 | Method of preventing UV-induced functional vitamin A deficiency by topical application of retinoids |
CA002344696A CA2344696A1 (en) | 1998-10-14 | 1999-10-12 | Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid |
BR9914531-6A BR9914531A (en) | 1998-10-14 | 1999-10-12 | Prevention of IV-induced functional vitamin A deficiency through the use of topically applied retinoid |
AU65133/99A AU6513399A (en) | 1998-10-14 | 1999-10-12 | Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid |
NO20011449A NO20011449L (en) | 1998-10-14 | 2001-03-22 | Method of Inhibiting UV-Induced Vitamin A Deficiency Using Topically Used Retinoid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10424598P | 1998-10-14 | 1998-10-14 | |
US60/104,245 | 1998-10-14 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000021486A2 true WO2000021486A2 (en) | 2000-04-20 |
WO2000021486A9 WO2000021486A9 (en) | 2000-11-23 |
WO2000021486A3 WO2000021486A3 (en) | 2007-08-23 |
Family
ID=22299409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/023591 WO2000021486A2 (en) | 1998-10-14 | 1999-10-12 | Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2003524604A (en) |
AU (1) | AU6513399A (en) |
BR (1) | BR9914531A (en) |
CA (1) | CA2344696A1 (en) |
IL (1) | IL142349A0 (en) |
WO (1) | WO2000021486A2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807900A (en) * | 1995-03-31 | 1998-09-15 | Hoffmann-La Roche, Inc. | Method for identifying compounds having increased activity for the repair of skin photodamage |
-
1999
- 1999-10-12 WO PCT/US1999/023591 patent/WO2000021486A2/en active Application Filing
- 1999-10-12 BR BR9914531-6A patent/BR9914531A/en not_active Application Discontinuation
- 1999-10-12 AU AU65133/99A patent/AU6513399A/en not_active Abandoned
- 1999-10-12 JP JP2000575462A patent/JP2003524604A/en not_active Withdrawn
- 1999-10-12 CA CA002344696A patent/CA2344696A1/en not_active Abandoned
- 1999-10-12 IL IL14234999A patent/IL142349A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807900A (en) * | 1995-03-31 | 1998-09-15 | Hoffmann-La Roche, Inc. | Method for identifying compounds having increased activity for the repair of skin photodamage |
Also Published As
Publication number | Publication date |
---|---|
IL142349A0 (en) | 2002-03-10 |
WO2000021486A9 (en) | 2000-11-23 |
CA2344696A1 (en) | 2000-04-20 |
WO2000021486A3 (en) | 2007-08-23 |
JP2003524604A (en) | 2003-08-19 |
BR9914531A (en) | 2001-07-03 |
AU6513399A (en) | 2000-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Selvam et al. | Low frequency and low intensity pulsed electromagnetic field exerts its antiinflammatory effect through restoration of plasma membrane calcium ATPase activity | |
Wang et al. | Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pre-treatment | |
CA2241981C (en) | Method of inhibiting photoaging of skin | |
Slominski et al. | On the role of melatonin in skin physiology and pathology | |
Tyrrell | Ultraviolet radiation and free radical damage to skin | |
Black et al. | UVB light regulates expression of antioxidants and inflammatory mediators in human corneal epithelial cells | |
Romero et al. | Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function | |
Jackson et al. | Ageing skin: oestrogen receptor β agonists offer an approach to change the outcome | |
Kim et al. | The effects of a novel synthetic retinoid, seletinoid G, on the expression of extracellular matrix proteins in aged human skin in vivo | |
US5998394A (en) | Compositions for treating skin conditions by enhancing the activity of 1,25(OH)2 D3 using an RXR ligand and/or a 24-hydroxylase inhibitor | |
Kramer-Stickland et al. | Effect of UVB on hydrolysis of α-tocopherol acetate to α-tocopherol in mouse skin | |
WO2009065141A1 (en) | Methods and compositions for reducing skin damage | |
WO2000021486A2 (en) | Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid | |
Mao et al. | Inhibition of the activity of a neuronal kappaB-binding factor by glutamate. | |
Welsh et al. | Topical all-trans retinoic acid augments ultraviolet radiation-induced increases in activated melanocyte numbers in mice | |
US7892777B2 (en) | Methods for measuring whether a treatment affects RPTP-κ activity | |
CA2326507A1 (en) | Methods and compositions for reducing uv-induced inhibition of collagen synthesis in human skin | |
US7141238B2 (en) | Compositions for reducing UV-induced inhibition of collagen biosynthesis in human skin | |
WO1993019729A1 (en) | Retinoic acid as a skin tanning agent in persons of light skin color | |
Yusifov et al. | Light exposure induces antioxidant enzyme activities in eye tissues of frogs | |
Liu et al. | Polypeptide from Chlamys farreri modulates UVB-induced activation of NF-κB signaling pathway and protection HaCaT cells from apoptosis | |
Ozolins̆ et al. | Tissue-specific regulation of glutathione homeostasis and the activator protein-1 (AP-1) response in the rat conceptus | |
Khvoryk et al. | Lipid peroxidation and antioxidant protection in patients with papulo-pustular rosacea | |
AU701132C (en) | Method of inhibiting photoaging of skin | |
Vilchis et al. | Identification and androgen regulation of a 156-kDa hemeprotein in the Harderian gland of the Syrian hamster |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 1999 65133 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BR CA CN HU IL IN JP KR MX NO RU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AU BR CA CN HU IL IN JP KR MX NO RU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
ENP | Entry into the national phase |
Ref document number: 2344696 Country of ref document: CA Kind code of ref document: A Ref document number: 2344696 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999953125 Country of ref document: EP Ref document number: 65133/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 142349 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2000 575462 Country of ref document: JP Kind code of ref document: A |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999953125 Country of ref document: EP |
|
122 | Ep: pct application non-entry in european phase |